Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
TransMedics Group $460 million convertible senior notes offering
The convertible senior notes are due 2028
ACELYRIN $621 million IPO
The stock is listed on the Nasdaq Global Select Market
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
Privia Health Group $936 million secondary offering
We advised Privia on the registered secondary offering
DexCom $1.25 billion convertible notes offering and capped call transactions
The 0.375% convertible senior notes are due 2028
Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen
We are advising Cellular Biomedicine Group on the transaction
Invacare chapter 11 plan confirmed
We advised the prepetition term loan agent and escrow agent on the transaction
MedSci Healthcare Holdings HK$608 million IPO
We advised MedSci on its IPO and HKEX listing